Mallinckrodt Pays $117M for This Bay Area Biotech and Its Failed Liver Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M. Source: BioSpace You Might Also Like Prime Therapeutics Urges Caution On Mandates Of Abuse-Deterrent Formulations Of Opioids Citing Value Concerns July 20, 2017 Onxeo Plunges After Liver Cancer Drug Fails Late-Stage Study September 11, 2017 Immutep Strikes Deal with Merck to Pair Product With Keytruda in Phase II Trial March 11, 2018
Prime Therapeutics Urges Caution On Mandates Of Abuse-Deterrent Formulations Of Opioids Citing Value Concerns July 20, 2017
